To Örebro University

oru.seÖrebro University Publications
Planned maintenance
A system upgrade is planned for 10/12-2024, at 12:00-13:00. During this time DiVA will be unavailable.
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Association between azathioprine use and risk of acute pancreatitis in pediatric inflammatory bowel disease: A nationwide Swedish cohort study
Karolinska Institutet, Stockholm, Sweden.
Statens Serum Institut, Copenhagen, Denmark.
Karolinska Institutet, Stockholm, Sweden; Karolinska Institutet, Stockholm, Sweden; Sachs' Children and Youth Hospital, Stockholm, Sweden.
Statens Serum Institut, Copenhagen, Denmark; University of Copenhagen, Copenhagen, Denmark; Stanford University School of Medicine, Stanford California, USA.
Show others and affiliations
2018 (English)In: Pharmacoepidemiology and Drug Safety, ISSN 1053-8569, E-ISSN 1099-1557, Vol. 27, no Suppl. 2, p. 196-196Article in journal, Meeting abstract (Other academic) Published
Abstract [en]

Background: Studies have shown an association between use of azathioprine and acute pancreatitis in adult inflammatory bowel disease. However, whether there is an association among pediatric patients isnot known.

Objectives: To investigate if there is an association between use of azathioprine and the risk of acute pancreatitis in pediatric inflammatory bowel disease (pIBD) patients.

Methods: We conducted a nationwide Swedish cohort study based on health care register data, 2006‐2014. From a cohort of all pediatric patients (<18 years) with IBD (n = 4631), we included 1477 episodes of new azathioprine use and 1477 episodes of no use in propensity score‐matched (1:1 ratio) analyses. The propensity score included patient characteristics, comorbidities, previous treatment, indicators of disease severity and health care utilization. Incident cases of acute pancreatitis occurring in the primary risk period of 90 days following treatment initiation were identified through outpatient and inpatient hospital records. A sensitivity analysis was restricted to inpatient cases alone. A secondary risk period of 91‐365 days following treatment initiation was also assessed. Cox proportional hazards models were used to estimate hazard ratios (HRs).

Results: Among azathioprine‐exposed, mean age was 14.3 (SD 3.2) years, 56.5% were male, and 56.1% had Crohn's disease and 43.9% had ulcerative colitis or IBD‐unclassified. During the first 90 days following azathioprine initiation, 23 patients (1.6%) experienced acute pancreatitis compared with 5 patients (0.3%) in the no use group; corresponding incidence rates were 65 and 16 per 1000 person‐years. The risk was significantly higher in patients with azathioprine use, HR = 4.21 (95% CI 1.60‐11.08). The HR was similar when only considering acute pancreatitis events in inpatient care (4.82 [1.65‐14.03]) and there was no increased risk during the period 91‐365 days following treatment initiation (0.36 [0.03‐4.01]).

Conclusions: Use of azathioprine was associated with an increased risk of acute pancreatitis in pIBD during the first 90 days of use but not later. The finding suggests that the risk of acute pancreatitis needs to be considered when deciding on optimal treatment strategy in pIBD. Additional analyses also including nationwide Danish data are ongoing and will be presented at the conference.

Place, publisher, year, edition, pages
John Wiley & Sons, 2018. Vol. 27, no Suppl. 2, p. 196-196
National Category
Public Health, Global Health, Social Medicine and Epidemiology Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:oru:diva-68968ISI: 000441893801194OAI: oai:DiVA.org:oru-68968DiVA, id: diva2:1249395
Conference
34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague Congress Centre, Prague, Czech Republic, August 22–26, 2018
Available from: 2018-09-19 Created: 2018-09-19 Last updated: 2020-12-01Bibliographically approved

Open Access in DiVA

No full text in DiVA

Authority records

Ludvigsson, Jonas F.

Search in DiVA

By author/editor
Ludvigsson, Jonas F.
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
Pharmacoepidemiology and Drug Safety
Public Health, Global Health, Social Medicine and EpidemiologyPharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 458 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf